Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

This study is for people with a type of stomach cancer called **gastric cancer** or **gastroesophageal junction (GEJ) adenocarcinoma**. The study looks at a medicine named **Infigratinib**. It's for people whose cancer has spread and didn't get better with at least two other treatments. Infigratinib targets cancer cells with a change in a gene called **FGFR2**. Only adults who can prove their diagnosis and have been through certain treatments are eligible. They will need a **biopsy**, which is a test where a small piece of the tumor is taken to look at in a lab. The study checks if the medicine works and if it's safe. Participants shouldn't have other serious health problems or be allergic to Infigratinib.

• The study requires patients to be over 18 years old and have tried at least two other treatments.
• Participants will need to undergo a tumor biopsy and have a life expectancy of at least 3 months.
• Compensation details aren't mentioned, but participants must understand and agree to the study rules.